{
  "guideline": {
    "id": "PA166104968",
    "name": "Annotation of DPWG Guideline for venlafaxine and CYP2D6",
    "source": "DPWG",
    "version": 33,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104968",
    "relatedChemicals": [
      {
        "id": "PA451866",
        "name": "venlafaxine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302881",
      "name": "Recommendation Annotation PA166302881",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104480,
        "html": "<p>It is not possible to offer adequately substantiated advice for dose reduction based on the literature.</p>\n<ul>\n<li>Avoid venlafaxine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n<li>If it is not possible to avoid venlafaxine and side effects occur:</li>\n</ul>\n<ol>\n<li>Reduce the dose</li>\n<li>Monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine.\nIt is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum.</li>\n</ol>\n"
      },
      "implications": [
        "There are indications of an increased risk of side effects and a reduced chance of efficacy. The gene variation reduces the conversion of venlafaxine to the active metabolite O-desmethylvenlafaxine, whilst an association between high O-desmethylvenlafaxine/venlafaxine ratios and response without side effects was found."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302890",
      "name": "Recommendation Annotation PA166302890",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104489,
        "html": "<ol>\n<li>Be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O- desmethylvenlafaxine.</li>\n<li>If necessary, increase the dose to 150% of the standard dose.</li>\n<li>If dose adjustment does not result in efficacy without unacceptable side effects or if dose adjustment based on therapeutic drug monitoring is not possible, then venlafaxine should be avoided.\nAntidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n</ol>\n"
      },
      "implications": [
        "It may be difficult to adjust the dose for patients due to altered metabolism between venlafaxine and the active metabolite O- desmethylvenlafaxine. The gene variation increases the conversion of venlafaxine to O-desmethylvenlafaxine and reduces the sum of venlafaxine plus O-desmethylvenlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302886",
      "name": "Recommendation Annotation PA166302886",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104485,
        "html": "<p>The guideline does not provide a recommendation for venlafaxine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on venlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302895",
      "name": "Recommendation Annotation PA166302895",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104494,
        "html": "<ol>\n<li>Be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O- desmethylvenlafaxine.</li>\n<li>If necessary, increase the dose to 150% of the standard dose.</li>\n<li>If dose adjustment does not result in efficacy without unacceptable side effects or if dose adjustment based on therapeutic drug monitoring is not possible, then venlafaxine should be avoided.\nAntidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n</ol>\n"
      },
      "implications": [
        "It may be difficult to adjust the dose for patients due to altered metabolism between venlafaxine and the active metabolite O- desmethylvenlafaxine. The gene variation increases the conversion of venlafaxine to O-desmethylvenlafaxine and reduces the sum of venlafaxine plus O-desmethylvenlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302882",
      "name": "Recommendation Annotation PA166302882",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104481,
        "html": "<p>It is not possible to offer adequately substantiated advice for dose reduction based on the literature.</p>\n<ul>\n<li>Avoid venlafaxine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n<li>If it is not possible to avoid venlafaxine and side effects occur:</li>\n</ul>\n<ol>\n<li>Reduce the dose</li>\n<li>Monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine.\nIt is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum.</li>\n</ol>\n"
      },
      "implications": [
        "There are indications of an increased risk of side effects and a reduced chance of efficacy. The gene variation reduces the conversion of venlafaxine to the active metabolite O-desmethylvenlafaxine, whilst an association between high O-desmethylvenlafaxine/venlafaxine ratios and response without side effects was found."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302891",
      "name": "Recommendation Annotation PA166302891",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104490,
        "html": "<ol>\n<li>Be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O- desmethylvenlafaxine.</li>\n<li>If necessary, increase the dose to 150% of the standard dose.</li>\n<li>If dose adjustment does not result in efficacy without unacceptable side effects or if dose adjustment based on therapeutic drug monitoring is not possible, then venlafaxine should be avoided.\nAntidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n</ol>\n"
      },
      "implications": [
        "It may be difficult to adjust the dose for patients due to altered metabolism between venlafaxine and the active metabolite O- desmethylvenlafaxine. The gene variation increases the conversion of venlafaxine to O-desmethylvenlafaxine and reduces the sum of venlafaxine plus O-desmethylvenlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302887",
      "name": "Recommendation Annotation PA166302887",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104486,
        "html": "<p>The guideline does not provide a recommendation for venlafaxine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on venlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302896",
      "name": "Recommendation Annotation PA166302896",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104495,
        "html": "<ol>\n<li>Be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O- desmethylvenlafaxine.</li>\n<li>If necessary, increase the dose to 150% of the standard dose.</li>\n<li>If dose adjustment does not result in efficacy without unacceptable side effects or if dose adjustment based on therapeutic drug monitoring is not possible, then venlafaxine should be avoided.\nAntidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n</ol>\n"
      },
      "implications": [
        "It may be difficult to adjust the dose for patients due to altered metabolism between venlafaxine and the active metabolite O- desmethylvenlafaxine. The gene variation increases the conversion of venlafaxine to O-desmethylvenlafaxine and reduces the sum of venlafaxine plus O-desmethylvenlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302883",
      "name": "Recommendation Annotation PA166302883",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104482,
        "html": "<p>It is not possible to offer adequately substantiated advice for dose reduction based on the literature.</p>\n<ul>\n<li>Avoid venlafaxine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n<li>If it is not possible to avoid venlafaxine and side effects occur:</li>\n</ul>\n<ol>\n<li>Reduce the dose</li>\n<li>Monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine.\nIt is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum.</li>\n</ol>\n"
      },
      "implications": [
        "There are indications of an increased risk of side effects and a reduced chance of efficacy. The gene variation reduces the conversion of venlafaxine to the active metabolite O-desmethylvenlafaxine, whilst an association between high O-desmethylvenlafaxine/venlafaxine ratios and response without side effects was found."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302892",
      "name": "Recommendation Annotation PA166302892",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104491,
        "html": "<ol>\n<li>Be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O- desmethylvenlafaxine.</li>\n<li>If necessary, increase the dose to 150% of the standard dose.</li>\n<li>If dose adjustment does not result in efficacy without unacceptable side effects or if dose adjustment based on therapeutic drug monitoring is not possible, then venlafaxine should be avoided.\nAntidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n</ol>\n"
      },
      "implications": [
        "It may be difficult to adjust the dose for patients due to altered metabolism between venlafaxine and the active metabolite O- desmethylvenlafaxine. The gene variation increases the conversion of venlafaxine to O-desmethylvenlafaxine and reduces the sum of venlafaxine plus O-desmethylvenlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302879",
      "name": "Recommendation Annotation PA166302879",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104478,
        "html": "<p>It is not possible to offer adequately substantiated advice for dose reduction based on the literature.</p>\n<ul>\n<li>Avoid venlafaxine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n<li>If it is not possible to avoid venlafaxine and side effects occur:</li>\n</ul>\n<ol>\n<li>Reduce the dose</li>\n<li>Monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine.\nIt is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum. Furthermore, a reduced effectiveness of venlafaxine has been observed in depression patients with this gene variation.</li>\n</ol>\n"
      },
      "implications": [
        "There are indications of an increased risk of side effects and a reduced chance of efficacy. The gene variation reduces the conversion of venlafaxine to the active metabolite O-desmethylvenlafaxine, whilst an association between high O-desmethylvenlafaxine/venlafaxine ratios and response without side effects was found."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302888",
      "name": "Recommendation Annotation PA166302888",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104487,
        "html": "<p>The guideline does not provide a recommendation for venlafaxine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on venlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302884",
      "name": "Recommendation Annotation PA166302884",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104483,
        "html": "<p>The guideline does not provide a recommendation for venlafaxine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on venlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302893",
      "name": "Recommendation Annotation PA166302893",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104492,
        "html": "<ol>\n<li>Be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O- desmethylvenlafaxine.</li>\n<li>If necessary, increase the dose to 150% of the standard dose.</li>\n<li>If dose adjustment does not result in efficacy without unacceptable side effects or if dose adjustment based on therapeutic drug monitoring is not possible, then venlafaxine should be avoided.\nAntidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n</ol>\n"
      },
      "implications": [
        "It may be difficult to adjust the dose for patients due to altered metabolism between venlafaxine and the active metabolite O- desmethylvenlafaxine. The gene variation increases the conversion of venlafaxine to O-desmethylvenlafaxine and reduces the sum of venlafaxine plus O-desmethylvenlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302880",
      "name": "Recommendation Annotation PA166302880",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104479,
        "html": "<p>It is not possible to offer adequately substantiated advice for dose reduction based on the literature.</p>\n<ul>\n<li>Avoid venlafaxine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n<li>If it is not possible to avoid venlafaxine and side effects occur:</li>\n</ul>\n<ol>\n<li>Reduce the dose</li>\n<li>Monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine.\nIt is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum.</li>\n</ol>\n"
      },
      "implications": [
        "There are indications of an increased risk of side effects and a reduced chance of efficacy. The gene variation reduces the conversion of venlafaxine to the active metabolite O-desmethylvenlafaxine, whilst an association between high O-desmethylvenlafaxine/venlafaxine ratios and response without side effects was found."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302889",
      "name": "Recommendation Annotation PA166302889",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104488,
        "html": "<ol>\n<li>Be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O- desmethylvenlafaxine.</li>\n<li>If necessary, increase the dose to 150% of the standard dose.</li>\n<li>If dose adjustment does not result in efficacy without unacceptable side effects or if dose adjustment based on therapeutic drug monitoring is not possible, then venlafaxine should be avoided.\nAntidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n</ol>\n"
      },
      "implications": [
        "It may be difficult to adjust the dose for patients due to altered metabolism between venlafaxine and the active metabolite O- desmethylvenlafaxine. The gene variation increases the conversion of venlafaxine to O-desmethylvenlafaxine and reduces the sum of venlafaxine plus O-desmethylvenlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302885",
      "name": "Recommendation Annotation PA166302885",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104484,
        "html": "<p>The guideline does not provide a recommendation for venlafaxine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on venlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302894",
      "name": "Recommendation Annotation PA166302894",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451866",
          "name": "venlafaxine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104493,
        "html": "<ol>\n<li>Be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O- desmethylvenlafaxine.</li>\n<li>If necessary, increase the dose to 150% of the standard dose.</li>\n<li>If dose adjustment does not result in efficacy without unacceptable side effects or if dose adjustment based on therapeutic drug monitoring is not possible, then venlafaxine should be avoided.\nAntidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</li>\n</ol>\n"
      },
      "implications": [
        "It may be difficult to adjust the dose for patients due to altered metabolism between venlafaxine and the active metabolite O- desmethylvenlafaxine. The gene variation increases the conversion of venlafaxine to O-desmethylvenlafaxine and reduces the sum of venlafaxine plus O-desmethylvenlafaxine."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2024-03-25-16-13"
}